BeOne Medicines outlines $5B-$5.3B 2025 revenue target as BRUKINSA leads BTK market and global expansion accelerates
Source: SeekingAlpha
2025-08-06 13:37:33 ET
More on BeiGene
- BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript
- BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field
- BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance
- BeiGene Q2 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on BeiGene
Read the full article on Seeking Alpha
For further details see:
BeOne Medicines outlines $5B–$5.3B 2025 revenue target as BRUKINSA leads BTK market and global expansion accelerates
BeiGene
NASDAQ: BEIGF
BEIGF Trading
0.0% G/L:
$23.75 Last:
100 Volume:
$23.75 Open:
BEIGF Latest News
BEIGF Stock Data
$38,603,023,416
747,457,849
N/A
299
N/A
Biotechnology & Life Sciences
Healthcare
CH
Basel
